J. Goldman & Co’s Halozyme HALO Stock Holding History

J. Goldman & Co’s Portfolio HALO Stock Details HALO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-269,176	Closed	-$2.66M	–	356
2016 Q4	$2.66M	Sell	269,176 -13,724	-5%	-$150K	0.18%	155
2016 Q3	$3.42M	Buy	+282,900	New	+$2.89M	0.19%	146

Other funds holding HALO

Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SAM

Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return

J. Goldman & Co's HALO Position: Q1 2017 in Review

J. Goldman & Co sold out of Halozyme (HALO) in Q1 2017, closing a stake of 269,176 shares — an estimated $2.66M sold.

J. Goldman & Co first reported a position in HALO in Q3 2016 and held it in 2 quarters. The position peaked at $3.42M in Q3 2016. 160 funds tracked by Wall St. Rank hold HALO as of Q1 2017.

J. Goldman & Co reported no remaining Halozyme position as of Q1 2017 after selling out during the quarter.
J. Goldman & Co sold 269,176 Halozyme shares in Q1 2017, an estimated $2.66M.
J. Goldman & Co first reported a position in Halozyme in Q3 2016 and held it in 2 quarters.
J. Goldman & Co's Halozyme position peaked at $3.42M in Q3 2016.
160 funds tracked by Wall St. Rank held Halozyme as of Q1 2017.

Based on J. Goldman & Co's 13F filing for Q1 2017, filed 15 May 2017.